KRMD KORU Medical Systems, Inc.

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0000704440
AI RATING
HOLD
65% Confidence

Investment Thesis

KORU demonstrates strong fundamentals with 22.2% revenue growth and exceptional 61.5% gross margins, indicating solid product-market fit and differentiation. However, the company remains unprofitable with negative free cash flow (-$31.5K) and operating losses (-$807.1K), creating execution risk. With $8.8M in cash and minimal debt, the balance sheet provides runway for growth investments, but management must demonstrate a credible path to profitability before positive cash flow inflection.

Strengths

  • + Strong revenue growth trajectory at 22.2% YoY with market traction
  • + Exceptional gross margins of 61.5% indicating strong pricing power and product differentiation
  • + Fortress balance sheet with $8.8M cash, 2.33x current ratio, and minimal debt leverage (0.03x D/E)
  • + Improving profitability trend with EPS loss declining 53.8% YoY, approaching breakeven

Risks

  • ! Negative free cash flow (-$31.5K) and operating cash flow insufficient to cover capex, indicating unsustainable burn rate
  • ! Current net losses of -$807.1K with -6.9% net margin require major operating leverage gains to reach sustainability
  • ! Operating expenses too high relative to revenue; 7.4% operating margin deficit must compress significantly while maintaining growth momentum
  • ! Potential need for future capital raise if cash burn accelerates or profitability timeline extends beyond current runway

Key Metrics to Watch

Financial Metrics

Revenue
11.8M
Net Income
-807.1K
EPS (Diluted)
$-0.02
Free Cash Flow
-31.5K
Total Assets
28.6M
Cash
8.8M

Profitability Ratios

Gross Margin 61.5%
Operating Margin -7.4%
Net Margin -6.9%
ROE -4.8%
ROA -2.8%
FCF Margin -0.3%

Balance Sheet & Liquidity

Current Ratio
2.33x
Quick Ratio
1.82x
Debt/Equity
0.03x
Debt/Assets
40.8%
Interest Coverage
-458.60x
Long-term Debt
439.3K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T10:51:44.698468 | Data as of: 2026-03-31 | Powered by Claude AI